

1646



Certificate of Mailing:  
The undersigned certifies that this correspondence is being sent via First-Class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 6th day of November, 2003.  
(s) Linda S. Evans  
Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thurmond et al. Atty. Docket: ORT-1555  
Serial No.: 10/036,648 Art Unit: 1646  
Filed: 21 December 2001 Examiner: Unknown  
For: Use of Histamine H4 Receptor Antagonist for the Treatment of Inflammatory Responses

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statement dated 28 January 2002 filed in the above-identified application. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(b)(3), i.e., before the mailing of a first Office Action on the merits. In the event that a first Office Action has been mailed, then this Statement is being filed under 37 C.F.R. § 1.97(c)(1) with the required statement as specified at 37 C.F.R. § 1.97(e).

Each reference listed on the enclosed form was first cited in a counterpart PCT application in an International Search Report from the European Patent Office as International Searching Authority not more than three months prior to the filing of this


Statement. A copy of the International Search Report is enclosed. Each reference is in the English language.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of each reference.

Respectfully submitted,

Date: November 6, 2003

  
Linda S. Evans  
Reg. No. 33,873

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, New Jersey 08933-7003  
(858) 320-3406

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

ORT-1555

SERIAL NO.

10/036,648

APPLICANT

Thurmond et al.

FILING DATE

21 December 2001

GROUP ART UNIT

1646

**INFORMATION DISCLOSURE  
CITATION BY APPLICANT**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
0 1 8 5 7 8 6	15 Nov. 2001	WO			
0 2 0 5 6 8 7 1	25 July 2002	WO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Liu et al., "Comparison of human, mouse, rat and guinea pig histamine H4 receptors reveals substantial pharmacological species variation", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 299, No. 1, pp. 121-130, 2001.
	Nakamura et al., "Molecular cloning and characterization of a new human histamine receptor, HH4R", <i>Biochemical and Biophysical Research Communications</i> , Vol. 279, pp. 615-620, 2000.
	Oda et al., "Molecular cloning and characterization for a novel type of histamine receptor preferentially expressed in leukocytes", <i>Journal of Biological Chemistry</i> , Vol. 275, No. 47, pp. 36781-36786, 2000.
	O'Reilly et al., "Identification of a histamine H4 receptor on human eosinophils: role in eosinophil chemotaxis", <i>Journal of Receptors and Signal Transduction</i> , Vol. 22, No. 1-4, pp. 431-448.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.